Drug approvals at the FDA have looked different in 2026, with fewer public hearings and more closed-door decisions. So when the agency told the world Thursday it will hold an open advisory panel on Moderna's mRNA flu vaccine, that schedule update was the story, not the science.
An FDA advisory committee will meet on June 18 to debate mRNA-1010, Moderna's seasonal flu vaccine. The agency still has to deliver an approval decision by August 5.
Why The Hearing Matters More Than The Vote
Advisory panel hearings used to be a standard step before a new vaccine reached the market. Under the current administration, the FDA has often skipped them and leaned on internal review instead.
Convening one for Moderna is the agency's clearest signal yet that it wants this decision on mRNA-1010 to live in public view, after a string of controversies over how recent vaccine calls were made. That matters for Moderna because the path here has been bumpy, starting with a refuse-to-file letter in February that the FDA then reversed days later.
The reversal came with a split structure. Adults 50 to 64 will be assessed for full approval, while adults 65 and older go through accelerated approval with a required post-marketing study to keep that nod.
We break down regulatory shifts like this every weekday in Market Briefs - and you get a free 45-minute investing masterclass when you sign up.
The Numbers Behind The Shot
Moderna's Phase 3 study enrolled more than 40,000 adults aged 50 and older. The company's data showed mRNA-1010 was about 27% more effective than GSK's Fluarix, the standard licensed flu vaccine used as the comparator.
The product also gives Moderna a chance to reduce its reliance on Covid revenue, which has shrunk every year since 2022. A green light by August would put mRNA-1010 in pharmacies in time for the 2026-2027 flu season and reopen a revenue stream Citi analysts had described as "in limbo."
It would also be a proof point for the broader mRNA platform Moderna has tried to sell investors on for years.
What To Watch
The panel vote is non-binding, but the tone of the meeting tends to move the stock. Investors will watch how committee members talk about the older-adult data, since that is the group with the accelerated-approval label and a required follow-up study.
The other thing to watch is the framing the FDA itself uses, since this is the agency's first big public test on an mRNA product in months. The decision is due by August 5, and the signal is coming in June.
For daily reads on what FDA moves like this actually mean for the stocks involved, join Market Briefs - it comes with a free investing course as a sign-up bonus.
